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Severe Acute Respiratory 
Syndrome Coronavirus 2 Human 
Challenge Trials: Too Risky, 
Too Soon
To the Editor—Eyal et  al [1] have re-
cently argued that researchers should 
consider conducting severe acute respi-
ratory syndrome coronavirus 2 (SARS-
CoV-2) human challenge studies to 
hasten vaccine development. We have 
conducted (J. L.) and overseen (L. D.) 
human challenge studies and agree that 
they can be useful in developing anti-in-
fective agents. We also agree that adults 
can autonomously choose to undergo 
risks with no prospect of direct ben-
efit to themselves. However, we disagree 
that SARS-CoV-2 challenge studies are 
ethically appropriate at this time, for 3 
reasons: (1) current scientific knowledge 
of SARS-CoV-2 infection is insufficient 
to manage risks; (2) autonomous deci-
sion making, while necessary, does not 
override concerns about risk; and (3) un-
dertaking challenge studies now would 
imperil confidence in the research enter-
prise, potentially undermining the global 
response to the coronavirus disease 2019 
(COVID-19) pandemic.
Current scientific knowledge is in-
sufficient to manage the risks of severe 
disease or death among volunteers in 
SARS-CoV-2 human challenge studies, 
especially in terms of selecting low-risk 
volunteers [2]. New risks of COVID-19 
continue to emerge, such as unexpected 
cardiovascular events [3] and strokes 
in otherwise healthy, young people [4]. 
Selecting a proper dose for a challenge 
study while protecting volunteers would 
be difficult given the high variability 
in patient responses [5]. There are no 
highly effective treatments, nor is there 
information about long-term health con-
sequences of infection.
Eyal et  al [1] allude to other research 
involving risks of severe disease or death, 
including human challenge studies for 
other diseases. But such studies—for 
example, malaria challenge trials—min-
imize and manage risks to volunteers 
by using well-characterized pathogens 
with known clinical sequelae in pains-
takingly defined subpopulations [6]. 
Malaria treatment with Food and Drug 
Administration–approved drugs is 
readily available, and decades of research 
enable selection of low-risk volunteers. 
Even so, unexpected events can happen: a 
genetic polymorphism affecting metabo-
lism of the malaria treatment primaquine 
was found in a challenge study [7]. Had 
the disease been poorly understood, the 
results could have been catastrophic.
It is not obvious that the possible bene-
fits of developing a successful vaccine in 
less time justify the risks SARS-CoV-2 
challenge studies, as Eyal and colleagues 
suggest [1]. There is no guarantee that 
any trial, or series of trials, will produce a 
viable vaccine: consider vaccine research 
for human immunodeficiency virus or 
hepatitis C. There is also little precedent 
for the Food and Drug Administration 
to license a vaccine primarily based on 
evidence from challenge studies (recent 
approval of a cholera vaccine is an excep-
tional case [8]). Even promising results 
in challenge studies may not correlate 
with population-level effects [9], and ad-
ditional field trials would be needed. If a 
vaccine is proved effective, obstacles to 
production and distribution might limit 
how many lives it saves [10].
Autonomous authorization (informed 
consent) is essential for protecting re-
search volunteers’ rights, and Eyal et  al 
emphasize the legitimacy of a ma-
ture person’s choice to accept risk [1]. 
However, people often make decisions 
in irrational or idiosyncratic ways—
in life generally [11], and in research. 
Volunteers often believe that unproven 
experimental treatments will medically 
benefit them (therapeutic misconcep-
tion [12]) or that unproven vaccines 
will protect against infection (preventive 
misconception [13]). Altruistic volun-
teers who sign up for potential challenge 
studies [14] amidst the global COVID-19 
pandemic may also suffer from a mis-
conception—an overconfidence that the 
research will provide substantial societal 
benefit [15]. Given the inherent uncer-
tainty in vaccine development, this kind 
of optimistic bias could lead people to 
take risks without seeing the associated 
benefits, in conflict with their core values 
and interests. Furthermore, volunteers 
who have a change of heart after being in-
fected with SARS-CoV-2 would have no 
opportunity to withdraw from the study 
that would reduce risk [16].
Beyond concerns about decision 
making, SARS-CoV-2 human challenge 
studies have the potential to be exploitative. 
There are disparities in power, informa-
tion, and control between researchers and 
volunteers [17]. Economically disadvan-
taged people are often willing to join trials 
despite discomforts and risks because 
financial compensation is offered [18]. 
Thus, vulnerable members of the public 
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might bear a disproportionate burden of 
risks that are unjustifiably high.
Eyal et al [1] compare volunteering in 
a SARS-CoV-2 human challenge study to 
firefighting and living kidney donation, 
activities that are permissible despite 
their risks [19]. However, there are im-
portant differences between research and 
nonresearch activities. Clinical research 
is a complex, fragile enterprise based on 
shared understanding of risks, burdens, 
benefits, and values among diverse stake-
holders [20]. In addition to rigorous re-
search oversight, the research enterprise 
depends on stakeholders’ mutual trust 
and willingness to adhere to certain ex-
pectations, including that researchers will 
prioritize the safety of study volunteers 
[21]. The fragility of the enterprise is due 
in part to issues noted: idiosyncrasies of 
human decision making, uncertain risks 
and benefits, and potential exploitation.
When study volunteers die or suffer 
serious harm at the hands of researchers, 
investigators themselves become com-
plicit, potentially undermining the 
stakeholders’ confidence in the research 
enterprise. One very bad outcome not 
only harms the individual volunteer, it 
harms the whole research process [22], 
and public trust is likely to plummet [23]. 
Violations of public trust have ripple ef-
fects on research, public health efforts, 
and clinical care.
The current landscape facing the re-
search and public health communities 
is fraught. Mistrust of research and of 
vaccines in particular is rampant; con-
spiracy theories, misinformation, and 
anti-science attitudes are spreading. 
Bad outcomes in a SARS-CoV-2 human 
challenge study could be devastating, as 
recent experience demonstrates that mis-
trust interferes with public health efforts 
in epidemic conditions [24].
Although SARS-CoV-2 human chal-
lenge studies are not ethically accept-
able at present, this may change if the 
following conditions are met: (1) better 
characterization of factors leading to se-
vere disease and death in SARS-CoV-2 
infection, to definitively screen out 
high-risk volunteers; (2) availability of 
proved effective treatment to prevent 
severe disease and disease; (3) a clearer 
understanding of protective effects of im-
munity and the elucidation of the goal of 
a vaccine to guide dosing and end-point 
selection; and (4) a public engagement 
strategy to address the challenge study 
and the risks to participants. We agree 
that solutions to the COVID-19 pan-
demic must be expedited, and we advo-
cate for efficient research and regulatory 
processes to support that goal. However, 
conducting SARS-CoV-2 human chal-
lenge trials now unjustifiably threatens 
both the well-being of volunteers and 
confidence in the research enterprise.
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Response to Dawson et al
To the Editor—Dawson et al [1] raise 
3 concerns about human challenge trials 
to assess the efficacy of severe acute 
respiratory syndrome coronavirus 2 
(SARS-CoV-2) vaccines. First, that cur-
rent scientific understanding is insuffi-
cient to know all the risks to volunteers, 
including potential long-term effects. 
However, assuming that the effects of 
artificial infection resemble those of 
natural infection, there is substantial ev-
idence that, so long as only young and 
healthy people are recruited [2–5], the 
risk of death is comparable to that of 
live kidney donation [6–8]. Known and 
unknown nonlethal complications fol-
lowing infection are also possible, but 
based on the evidence to date, among 
young people, complications within the 
duration of follow-up that has been pos-
sible in the first months of this pandemic 
are likely to remain rare. It would be 
imperative that volunteers in challenge 
studies have a clear understanding of the 
known risks and of the possibility of yet 
unrecognized risks. That includes long-
term risks whose frequency is unknow-
able, a familiar complication inherent 
in all first-in-human trials—including 
any phase III trials of novel SARS-Cov-2 
vaccines.
Second, Dawson et  al [1] question 
whether autonomous decision making by 
volunteers overrides concerns about risk, 
given that “people often make decisions 
in irrational or idiosyncratic ways,” sug-
gesting that irrational decisions are like-
lier in this case than elsewhere. We note 
that >28 000 individuals have already de-
clared willingness to participate in SARS-
Cov-2 challenge trials [9] and we think it 
unlikely that all of these are acting irra-
tionally. Of course, not all may be suit-
able for a challenge trial, and a thorough 
informed consent process should make 
a determination on each selected can-
didate. Procedures for obtaining fully 
comprehending consent, familiar to re-
search ethics since the 1980s, have been 
well established for novel interventions, 
including those for which risks are ill 
defined. Dawson et  al note, “Given the 
inherent uncertainty in vaccine develop-
ment, this kind of optimistic bias could 
lead people to take risks without seeing 
the associated benefits” [1]. However, this 
concern could apply to first-in-human 
vaccine trials, and even in phase 3 SARS-
Cov-2 vaccine trials, there is, for example, 
an uncertain risk of the vaccine inducing 
enhancing coronavirus disease 2019 
(COVID-19) disease [10].
Third, Dawson et  al consider that the 
conduct of challenge studies would im-
peril public confidence in the COVID-
19 research enterprise, potentially 
undermining the global response to 
the COVID-19 pandemic [1]. This we 
question. So long as investigators are 
open about the possibility of rare events 
occurring and this is made public knowl-
edge, if these events do occur rarely (as 
might also happen in conventional vac-
cine trials), we think it unlikely that 
COVID-19 research or public health re-
sponse would be affected, even if a rare 
volunteer did experience serious disease 
or death as a result of participation.
We recognize that challenge trials 
would raise fewer ethical worries if it were 
possible to exclude all volunteers at high 
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